Screening of janus kinase inhibitors for treatment of general myocarditis and other inflammatory cardiac conditions

WO2026064292A1PCT designated stage Publication Date: 2026-03-26RGT UNIV OF CALIFORNIA
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-09-16
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

Current treatments for acute fulminant myocarditis (AFM) and other inflammatory cardiac conditions are inadequate, with no approved medical therapy and corticosteroids showing limited efficacy, necessitating a need for better therapeutic methods.

Method used

Screening assays are developed to identify patients responsive to JAK inhibitors by measuring JAK/STAT signaling in pathogenic NK cells, CCR2+/HLA-DR+ intermediate monocytes, and activated T cells, and administering a therapeutically effective amount of JAK inhibitors such as ruxolitinib to reduce these cells and suppress STAT1/STAT3 signaling.

Benefits of technology

The method effectively identifies responsive patients and reduces pathogenic cell numbers and immune-cytotoxicity, potentially improving cardiac function and survival in inflammatory cardiac conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025046540_26032026_PF_FP_ABST
    Figure US2025046540_26032026_PF_FP_ABST
Patent Text Reader

Abstract

Methods and compositions are provided for screening candidate janus kinase (JAK) inhibitors for efficacy in treating myocarditis and other inflammatory cardiac conditions. Screening assays may include identifying patients who will be responsive to treatment of an inflammatory cardiac condition with a JAK inhibitor and determining the effectiveness of candidate JAK inhibitors in reducing numbers of pathogenic natural killer (NK) cells, CCR2+ / HLA-DR+ intermediate monocytes, and activated T cells as well as suppressing STAT1 / STAT3 signaling and expression of genes that mediate immune-cytotoxicity, such as perforin-1 (PRF1), granzyme B (GZMB), T-box transcription factor 21 (TBX21), and natural killer cell granule protein 7 (NKG7).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods for predicting drug responsiveness in samples from cancer subjects

    US20220308062A1